Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
- PMID: 36379204
- DOI: 10.1016/j.ccell.2022.10.014
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
Abstract
Sklavenitis-Pistofidis et al. report clinical and correlative results of a single-arm phase II trial of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering myeloma. The authors explore the interactions between the genetics of the plasma cell clone and the immune microenvironment as potential biomarkers of treatment susceptibility and efficacy.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.Cancer Cell. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017. Cancer Cell. 2022. PMID: 36379208 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
